Large Pharma Clinical Development and Commercialization for Global Biopharmaceutical Leaders
With the scale and complexity of today’s global portfolios and market landscape, large pharma organizations need more than execution. They need a proven partner who works as an extension of the team, bringing expertise, agility and accountability to keep critical programs moving forward.
Syneos Health moves with you — leading with expertise and acting with agility. Our teams combine therapeutic expertise, global operational scale, proactive partnership and commercial fluency to help navigate complexity, anticipate challenges and advance programs that matter for patients everywhere.
Why Large Pharmaceutical Companies Choose Syneos Health
Agility that Scales
We design around the challenge and adapt without losing momentum. Our operating model scales to meet portfolio complexity while staying responsive to each program’s needs.
Committed Team
We work as part of your team, with shared ownership of outcomes. Our teams stay aligned on goals, execution and performance so partnership value compounds across engagements.
Proactive Guidance
We speak up early, anticipate what is next and quickly shape solutions. Technology sharpens foresight, while experienced teams translate signals into practical action.
Market Fluency
We bring intelligence and sound judgment across therapeutic nuance, regulatory requirements, market dynamics and stakeholder engagement, helping teams make smarter decisions in complex environments.
Precision Performance
We apply AI-enabled workflows, predictive intelligence and proprietary technology to optimize what works, predict what matters and automate execution where it is designed to improve speed and efficiency from development to launch and beyond.
Comprehensive Development and Commercialization Solutions
Wherever we engage — a single asset, multi-asset program or enterprise portfolio — Syneos Health helps large pharma teams connect clinical development, evidence generation, regulatory and safety support, medical affairs and commercialization strategy into a more coordinated path forward.
- Clinical development: science-led, technology-enabled execution across global trials, FSP models, data management, biostatistics and Phase I-IV programs.
- Medical affairs and evidence generation: scientific engagement, publications, real-world evidence strategies and evidence planning that support stakeholder confidence.
- Regulatory, safety and pharmacovigilance: embedded expertise to help programs move across markets without losing ground.
- Commercialization services: predictive intelligence, omnichannel engagement, communications, market access, field deployment and healthcare analytics to support launch readiness, adoption strategies and commercial growth objectives.
- Integrated execution: shared visibility across data, channels, teams and functions so large pharma programs remain aligned as conditions change.
Built for Enterprise Partnerships
Large pharmaceutical organizations require consistency, transparency and scalability. Syneos Health supports enterprise relationships through a partnership model designed to create stability, sustain momentum and measure success by customer outcomes.
- Executive governance and program-level PMOs that create clarity, accountability and faster decisions.
- Scalable operating models that flex across assets, functions, markets and phases without adding unnecessary friction.
- Experienced functional leaders and dedicated teams that create continuity, transparency and stability across programs.
- Flexible FSP partnerships across biometrics, safety, regulatory, medical writing and operational functions.
- Flexible, scalable field teams that adapt rapidly to changing market conditions, product launches and lifecycle needs, helping large pharmaceutical companies turn outsourced commercialization into a strategic growth lever.
- Unified data and performance visibility so teams work from the same information at the same time.
Regulatory, Safety and Evidence Integration
Programs that span regions, phases and functions require market-specific judgment and consistent execution. Syneos Health brings regulatory, safety, evidence and market fluency together so development decisions remain connected to real-world conditions and stakeholder expectations.
- Proactive global regulatory engagement and submission planning.
- End-to-end drug safety and pharmacovigilance services.
- Evidence strategies that connect scientific, operational and commercial priorities.
- Integrated insights to support labeling, payer evidence and stakeholder engagement.
- Data integrity, privacy and quality controls across global clinical trials and commercialization programs.
Your Proven Partner for Large Pharma Success
Move forward with a partner built for the pace and complexity of large pharma. Syneos Health brings the expertise, agility, accountability and market fluency to support confident decision-making across critical programs — from clinical development through evidence generation, launch and beyond.
Frequently Asked Questions
A large pharma CRO is a contract research organization that supports global pharmaceutical companies with clinical development, medical affairs, regulatory, evidence generation and commercialization services across complex, multi-asset portfolios and international markets.
A large pharma CRO supports global pharmaceutical companies by delivering clinical development and commercialization services at enterprise scale across multi-asset portfolios, complex therapeutic areas and global markets. For large organizations, the right partner must connect operational delivery with scientific, medical, regulatory, evidence and commercial judgment.
As one of the few CROs that offers the full spectrum of services spanning clinical development, medical affairs, regulatory, evidence generation and commercialization within a single integrated organization, Syneos Health helps large pharmaceutical companies simplify complexity, maintain continuity and accelerate decision-making across the product lifecycle. Syneos Health is built to support that complexity. Our integrated model is designed to flex without losing momentum, combining advanced technology, real-time analytics and deep operational experience to identify risks early, adapt quickly and maintain progress as priorities evolve.
A large pharma CRO must deliver at enterprise scale across complex, multi-asset portfolios and global markets. Syneos Health supports this need as a proven partner built to move — combining clinical, medical, regulatory, evidence and commercial expertise with scalable operations, proactive guidance and market fluency.
Syneos Health supports large pharmaceutical companies by working as an extension of the team, aligning around goals, sharing ownership of outcomes and helping programs maintain momentum as conditions change. Services span clinical development, regulatory and safety, evidence generation, medical affairs, commercialization, market access and analytics.
Syneos Health offers clinical development services, functional service provider models, data management, biostatistics, real-world evidence, regulatory strategy, pharmacovigilance, medical affairs, commercialization services, omnichannel engagement, communications, field deployment, market access and healthcare analytics.
Syneos Health applies AI within clinical and commercial workflows to help teams move from insight to action. Our AI-enabled capabilities combine predictive intelligence, real-time analytics, proprietary data and advanced technology to surface signals earlier, support smarter planning and strengthen decision-making. Grounded in our Precision Performance approach, these capabilities are designed to predict what matters, optimize what works and automate execution, helping teams make better decisions, act with greater confidence and improve performance across the therapeutic lifecycle. Human expertise, oversight and responsible AI principles remain central to how these capabilities are deployed.
Syneos Health improves speed and efficiency through agile operating models, early risk identification, shared visibility, disciplined governance, flexible FSP support, risk-based monitoring and proactive guidance. The goal is to keep programs moving without adding unnecessary friction.
Market fluency helps large pharma teams navigate regional requirements, therapeutic nuance, stakeholder expectations, access dynamics and commercialization realities. Syneos Health applies market-specific judgment so strategies remain practical, coordinated and connected to real-world execution.
A large pharmaceutical company should consider an enterprise CRO partnership when it needs scalable delivery across multiple assets, geographies, functions or therapeutic areas; stronger governance; improved data visibility; flexible functional support; or a partner that can adapt quickly while maintaining momentum and accountability.
Large pharma companies should look for a CRO partner with scalable global delivery, therapeutic expertise, proactive guidance, flexible FSP support, data-enabled visibility, market fluency and an operating model that can adapt as portfolio priorities evolve.
An integrated clinical and commercial model helps large pharma teams connect development strategy, evidence needs, stakeholder expectations and launch planning earlier. This can support more coordinated decisions across the product lifecycle.
